However, the subsequent Phase III SKYSCRAPER-01 trial in PD-L1–high, first-line NSCLC did not meet its primary endpoints, as tiragolumab plus atezolizumab failed to show statistically significant improvements in progression-free survival (7.0 vs. 5.6 months; HR 0.78, p = 0.02) or overall survival (23.1 vs. 16.9 months; HR 0.87, p = 0.22), though numerical trends suggested potential antitumor activity [138]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.